Extreme Borrow Market Stress for RGC
Data from the Interactive Brokers stock-loan availability dataset as of September 23, 2026, highlights Regencell Bioscience (RGC) as the most expensive stock to borrow in the US market. With an annualized borrow fee of 237.82%, the cost to maintain a short position has become prohibitive for most market participants. Fees exceeding 100% typically signal that the borrow market has effectively closed, making it nearly impossible for new shorts to enter without significant capital or specialized access.
Short Interest and Squeeze Risk
While the short interest as a percentage of float remains relatively modest at 1.8%, the extreme cost of carry creates a high-pressure environment. The current squeeze score of 28 suggests that any positive price momentum could trigger a rapid covering cycle, as the cost to maintain these bearish bets is unsustainable for most institutional and retail traders. Investors should monitor the borrow availability closely, as further declines in lendable supply could lead to a parabolic move in the share price.
Signal data sourced from Tapeboard. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.